Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Lancet Oncol. 2024 Jun;25(6):e270-e280. doi: 10.1016/S1470-2045(24)00038-X.
Although radiotherapy continues to evolve as a mainstay of the oncological armamentarium, research and innovation in radiotherapy in low-income and middle-income countries (LMICs) faces challenges. This third Series paper examines the current state of LMIC radiotherapy research and provides new data from a 2022 survey undertaken by the International Atomic Energy Agency and new data on funding. In the context of LMIC-related challenges and impediments, we explore several developments and advances-such as deep phenotyping, real-time targeting, and artificial intelligence-to flag specific opportunities with applicability and relevance for resource-constrained settings. Given the pressing nature of cancer in LMICs, we also highlight some best practices and address the broader need to develop the research workforce of the future. This Series paper thereby serves as a resource for radiation professionals.
尽管放射治疗作为肿瘤学武器库的主要手段之一不断发展,但在低收入和中等收入国家(LMICs)的放射治疗研究和创新仍面临挑战。本第三篇专题论文审视了目前 LMIC 放射治疗研究的现状,并提供了国际原子能机构在 2022 年进行的一项调查的新数据以及关于资金的新数据。在与 LMIC 相关的挑战和障碍的背景下,我们探讨了一些发展和进步,例如深度表型分析、实时靶向和人工智能,以确定具有资源有限环境适用性和相关性的特定机会。鉴于癌症在 LMICs 中的紧迫性质,我们还强调了一些最佳实践,并解决了更广泛的需要,即为未来的研究人员队伍发展提供支持。因此,本专题论文为放射专业人员提供了一个资源。